Login to Your Account

Other News To Note

Monday, August 5, 2013

• Thallion Pharmaceuticals Inc., of Dorval, Quebec, said the effective net cash in the amended agreement for its acquisition by Bellus Health Inc., of Laval, Quebec, equals at least $7.5 million, including proceeds from the exercise or cancellation of "in-the-money" options of approximately $500,000, resulting in at least $0.1765 per common share in cash to Thallion's shareholders.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription